Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Dec;7(6):519-23.
doi: 10.1111/j.1742-481X.2010.00725.x. Epub 2010 Aug 17.

Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study

Affiliations
Clinical Trial

Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study

Hewa Fonsekage Sanjeewani Fonseka et al. Int Wound J. 2010 Dec.

Abstract

Oral phenytoin is an extensively used medicine for the treatment of convulsive disorders. Topical phenytoin has also been used for various types of ulcers. To determine the effectiveness of 2% topical phenytoin sodium solution in treating recalcitrant pyoderma gangrenosum. Six patients with treatment-resistant pyoderma gangrenosum who attended to Dermatology Unit/Ward were taken to the study and applied topical 2% phenytoin sodium solution to the wounds alone with other systemic therapy. Response to the treatment was assessed weekly. Three patients had idiopathic PG and other three had secondary diseases. At the end of the 4th week four patients showed complete resolution of the ulcers whereas other two patients showed the partial resolution. No adverse effects were noted. Phenytoin sodium 2% solution is beneficial for pyoderma gangrenosum (PG) with various etiologies. It enhanced the healing of the ulcer especially when the patient has treatment resistant disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient 1 – before treatment.
Figure 2
Figure 2
Patient 1 – after 4 weeks.
Figure 3
Figure 3
Patient 2 – after 1 week.
Figure 4
Figure 4
Patient 2 – after 4‐week treatment.
Figure 5
Figure 5
Patient 6 – before treatment.
Figure 6
Figure 6
Patient 6 after 4‐week treatment. There is evidence of surface reduction and healthy granulation tissue which was not achieved while using topical betamethasone.

Similar articles

Cited by

References

    1. Bolognia JL, Jorizzo JL, Rapini RP. Neutrophilic dermatoses. Dermatology. Vol 2 . St. Louis: Mosby, 2008:383–84.
    1. Bolognia JL, Jorizzo JL, Rapini RP. Neutrophilic dermatoses. Dermatology. Vol 2 . St. Louis: Mosby, 2008:386.
    1. Powell FC, Collins S. Pyoderma gangernosum. Clin Dermatol 2000;18:283–93. - PubMed
    1. Duffill MB. Cyclosporine, azathiorine and local therapy for pyoderma gangrenosum. Australas J Dermatol 2007;35:15–8. - PubMed
    1. Newell LM, Malkinson FD. Pyoderma gangrenosum cyclophosphamide therapy. Arch Dermatol 1983;119:495–7. - PubMed

Publication types

MeSH terms